DK1409021T3 - Formulering omfattende fulvestrant - Google Patents

Formulering omfattende fulvestrant

Info

Publication number
DK1409021T3
DK1409021T3 DK02745579T DK02745579T DK1409021T3 DK 1409021 T3 DK1409021 T3 DK 1409021T3 DK 02745579 T DK02745579 T DK 02745579T DK 02745579 T DK02745579 T DK 02745579T DK 1409021 T3 DK1409021 T3 DK 1409021T3
Authority
DK
Denmark
Prior art keywords
formulation
fulvestrant
oestra
17beta
triene
Prior art date
Application number
DK02745579T
Other languages
English (en)
Inventor
Paul Richard Gellert
Alison Margaret Potts
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1409021T3 publication Critical patent/DK1409021T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
DK02745579T 2001-07-07 2002-07-03 Formulering omfattende fulvestrant DK1409021T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116620.6A GB0116620D0 (en) 2001-07-07 2001-07-07 Formulation
PCT/GB2002/003084 WO2003006063A2 (en) 2001-07-07 2002-07-03 Formulation comprising fulvestrant

Publications (1)

Publication Number Publication Date
DK1409021T3 true DK1409021T3 (da) 2008-02-11

Family

ID=9918096

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745579T DK1409021T3 (da) 2001-07-07 2002-07-03 Formulering omfattende fulvestrant

Country Status (12)

Country Link
US (1) US20040175402A1 (da)
EP (1) EP1409021B1 (da)
JP (1) JP4295087B2 (da)
AT (1) ATE378070T1 (da)
AU (1) AU2002317298A1 (da)
CY (1) CY1107142T1 (da)
DE (1) DE60223542T2 (da)
DK (1) DK1409021T3 (da)
ES (1) ES2294146T3 (da)
GB (1) GB0116620D0 (da)
PT (1) PT1409021E (da)
WO (1) WO2003006063A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112837A1 (ja) * 2003-05-23 2004-12-29 Hisamitsu Pharmaceutical Co., Inc. 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン－１α生成抑制剤
JP5133064B2 (ja) * 2005-01-05 2013-01-30 國防教育研究基金会 ウリジン２リン酸（ｕｄｐ）−グルクロン酸転移酵素２ｂ（ｕｇｔ２ｂ）の抑制剤及び促進剤
WO2007033434A1 (en) * 2005-09-26 2007-03-29 Hospira Australia Pty Ltd Fulvestrant formulation
KR20070088695A (ko) * 2005-10-05 2007-08-29 시코르, 인크. 풀베스트란트 이성질체의 분리 방법
KR20100121505A (ko) 2008-03-07 2010-11-17 싸이도우스 엘엘씨. 플배스트랜 제제
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US9029582B2 (en) 2011-05-20 2015-05-12 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2015157752A1 (en) * 2014-04-11 2015-10-15 Sam Houston State University Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
WO2003006063A3 (en) 2003-05-15
EP1409021B1 (en) 2007-11-14
AU2002317298A1 (en) 2003-01-29
ES2294146T3 (es) 2008-04-01
JP4295087B2 (ja) 2009-07-15
US20040175402A1 (en) 2004-09-09
EP1409021A2 (en) 2004-04-21
PT1409021E (pt) 2008-01-11
DE60223542D1 (de) 2007-12-27
JP2004521151A (ja) 2004-07-15
WO2003006063A2 (en) 2003-01-23
GB0116620D0 (en) 2001-08-29
DE60223542T2 (de) 2008-11-13
ATE378070T1 (de) 2007-11-15
CY1107142T1 (el) 2012-10-24

Similar Documents

Publication Publication Date Title
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
BG106833A (en) Fulvestrant formulation
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
NZ527157A (en) Compositions for delivering bisphosphonates
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
WO2004093795A3 (en) Compositions for delivery of drug combinations
HK1065714A1 (en) Compositions for delivery of drug combinations
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
HK1084941A1 (en) Compounds and their use
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MY145074A (en) Thiazolidin-4-one derivatives
MXPA05008913A (es) Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2002015959A3 (en) Compounds and compositions for delivering active agents
MXPA04000028A (es) Formulacion farmaceutica para la administracion intramuscular de fulvestrant.
WO2004004639A3 (en) A novel stable formulation
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration